Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 1,50 M
EBIT 2016 -21,5 M
Net income 2016 -20,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 4,30 M
EBIT 2017 -19,8 M
Net income 2017 -21,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 6,25x
Capi. / Sales2017 2,18x
Capitalization 9,37 M
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
01/12 IMMUNOCELLULAR THERAPEUTICS LTD : Latest Reports on ImmunoCellular Therapeutics ..
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers, O..
2016 IMMUNOCELLULAR THERAPEUTICS : Announces Management Changes
2016 IMMUNOCELLULAR THERAPEUTICS : Research Reports Initiation on Biotech Stocks -- C..
2016 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
2016 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
2016 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
2016 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Amendments to Articles of Inc. or Bylaws; Ch..
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Principal Financial Officer & VP-Finance
John S. Yu Director
Rahul Singhvi Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..797.83%9
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 091
CELLTRION, INC.--.--%10 773
LONZA GROUP AG1.87%10 358
SEATTLE GENETICS, INC.24.12%9 272
More Results